Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Professional Care Providers
- Remove Prevention Professionals
- Remove Advisory
- Remove Guidelines or Manual
- Remove Substance Abuse
- Remove English
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Buprenorphine
- Remove Prescription Drugs
- Remove Oxycodone
Main page content
Published: November 2021
This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.